In Brief This Week: Myriad Genetics, BioMarin; Quest; Genetic Analysis; Cedars-Sinai Medical Center, Exosome Diagnostics; More | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said this week that BioMarin Pharmaceutical will use its BRACAnalysis test in its pivotal Phase 3 clinical study for BMN 673, an orally active PARP-inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad has submitted an Investigational Device Exemption to the US Food and Drug Administration that would allow the BRACAnalysis test to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program, as required by FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.